AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00663013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
Study NCT01623479 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.03%
Description: Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Study NCT01682733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
Study NCT01682733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suturing System
Description: The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
Study NCT03843086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction
Description: This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)
Study NCT02991638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibrutinib
Description: Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
Study NCT02634385 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Renal Artery Embolization
Description: Patients will be receiving embolization prior to planned partial nephrectomy.
Study NCT02634385 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Partial Nephrectomy (Surgical Resection)
Description: Patients will be undergoing planned partial nephrectomy post embolization.
Study NCT00561132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium oxide
Description: Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
Study NCT00775996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorazepate Dipotassium 15mg Tablets
Study NCT00775996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clorazepate Dipotassium 15mg Tablets
Study NCT02798250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
Study NCT02798250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
Study NCT04491565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational video
Description: an interactive educational video was viewed by participants in the intervention arm.
Study NCT04100577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Today Not Tomorrrow Pregnancy and Infant Support Program
Description: The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
Study NCT03358251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pocket-X Gel
Description: Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
Study NCT03358251 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling and root planing
Description: Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
Study NCT00621361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Oral
Study NCT00621361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Intravenous
Study NCT00621361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenous
Study NCT02407392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
Study NCT02407392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non targeted quadrantic biopsies
Description: During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
Study NCT02891837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours.
Study NCT02891837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours.
Study NCT04392401 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of blood samples in order to create a biocollection
Description: Blood samples will be collected at admission in intensive care, at Day 3, Day 7, Day 12 and Day 20 during their hospitalization. Clinical data from routine care will be collected. Vital status will be assessed at Day 28 and Day 90.
Study NCT00709852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
Study NCT00709852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol (ProHance)
Description: Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
Study NCT01021215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: 1200 mg twice daily given orally (PO) for 6 days
Study NCT01021215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg twice daily given orally for 6 days
Study NCT01021215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01994655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing exercise
Description: We want to investigate the effects of exercise on climacteric symptoms
Study NCT01994655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doing exercise
Description: Doing exercise at least 6 months including walking, running, yoga etc.
Study NCT04545684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The person will have to imagine different scenarios of manual gripping
Study NCT04545684 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: The placebo group will imagine a place without the presence of humans.
Study NCT02679027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and upward (PTMU)
Description: The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
Study NCT02679027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protrude tongue maximally and downward (PTMD)
Description: The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
Study NCT03426605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label LAM-003
Description: LAM-003
Study NCT04611321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
Study NCT01423721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromihexine hydrochloride syrup
Description: syrup
Study NCT01423721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromihexine hydrochloride granules
Description: granules
Study NCT02567773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2881078
Description: GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
Study NCT02567773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
Study NCT02567773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
Study NCT03496831 — intervention group
Intervention type: DRUG
Intervention: Biologic Agents
Study NCT03125200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-502
Description: Intravenous Infusion
Study NCT02097082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STANZA Drug-eluting resorbable Scaffold
Study NCT00412061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Octreotide 30 mg intramuscularly (i.m.) every 28 days.
Study NCT00412061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Description: Octreotide 30 mg intramuscularly (i.m.) every 28 days.
Study NCT00412061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
Study NCT00412061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
Study NCT02388854 — intervention group
Intervention type: GENETIC
Intervention: SNPs analysis with Sanger sequencing
Description: Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
Study NCT01714531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Goal Management Training
Study NCT01714531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Attention-Control
Study NCT05338489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study NCT05338489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study NCT05338489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administered orally.
Study NCT02740374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: ROTEM coagulation assessment and guided transfusion management.
Study NCT02740374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard Coagulation Tests assessment and guided transfusion management
Study NCT01853774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored navigation
Study NCT00537693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy
Description: Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
Study NCT03367650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Blood sample and environmental survey
Description: The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
Study NCT03995693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solution ingestion
Description: Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
Study NCT03995693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constant load arm cranking
Description: The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
Study NCT03995693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expired gas sampling
Description: Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
Study NCT03995693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect respiratory calorimetry
Description: A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
Study NCT03995693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
Study NCT03995693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measure of maximal voluntary contraction force production
Description: Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
Study NCT03995693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measure of muscle electrical activity (EMG)
Description: Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
Study NCT02120053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Teeth extractions and conventional immediate complete denture placement
Study NCT02120053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone substitute material group
Description: Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
Study NCT00636896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine plus modafinil
Description: Olanzapine 10 mg/d plus modafinil 200 mg/d
Study NCT00636896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine plus placebo
Description: Olanzapine 10 mg/d plus placebo
Study NCT04183231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-caries varnish
Description: topical tooth varnish
Study NCT04054024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab
Description: 140 mg Erenumab
Study NCT04054024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline
Study NCT03392571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGC-Triple regimen
Description: gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
Study NCT02444403 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Police Education Program designed to align law enforcement and HIV prevention in Tijuana
Description: The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3).
Study NCT01747850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement/Cognitive Behavioral Therapy
Description: All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
Study NCT01747850 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Enhancement/Cognitive Behavioral Therapy
Description: All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
Study NCT01747850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).